Panion & Bf Biotech Inc. received notification from Chinese cooperative partner, Wego Shandong, that the National Medical Products Administration, NMPA approved the NDA submission for the renal new drug (Nephoxil) which is used for hyperphosphatemia in dialysis patients.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
96.5 TWD | -0.62% | +0.21% | -13.84% |
Mar. 14 | Panion & Bf Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 07 | Panion & Bf Biotech Inc. Approves Cash Dividend for 2023 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.84% | 254M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 1760 Stock
- News Panion & Bf Biotech Inc.
- Panion & Bf Biotech Inc. Announces Nephoxil Receives NMPA Acceptance for NDA Application Submission